中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 7
Jul.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(7): 1401-1406

Effectiveness and safety of apatinib mesylate combined with gemcitabine+cisplatin+camrelizumab in patients with advanced gallbladder cancer

DOI: 10.12449/JCH250726
  • 1a.

    Department of Hepatobiliary and Pancreatic Surgery

  • 1b.

    Department of Gastroenterology，Henan Provincial People’s Hospital，Zhengzhou University，Zhengzhou 450003，China

  • 2.

    Department of Hepatobiliary and Pancreatic Surgery，The Affiliated Cancer Hospital of Zhengzhou University，Zhengzhou 450008，China

Research funding:

National Natural Science Foundation of China (82103617);

Science and Technology Research of Henan Province (232301420056)

More Information
  • Corresponding author: LI Deyu， lidy0408@sohu.com （ORCID： 0000-0002-6165-2403）
  • Received Date: 2024-12-04
  • Published Date: 2025-07-25
    Abstract
  •   Objective  To investigate the clinical effectiveness and safety of apatinib mesylate combined with gemcitabine+cisplatin （GC） and camrelizumab in the treatment of advanced gallbladder cancer， and to provide evidence for the clinical treatment of patients with advanced gallbladder cancer.  Methods  A total of 75 patients with advanced gallbladder cancer admitted to Henan Provincial People’s Hospital and The Affiliated Cancer Hospital of Zhengzhou University from January 2022 to December 2023 were retrospectively included. According to treatment plans， they were divided into study group （apatinib mesylate combined with GC+camrelizumab） and control group （GC+camrelizumab）. The 1-year survival rate， objective response rate （ORR）， disease control rate （DCR）， progression-free survival （PFS）， overall survival （OS）， and adverse reactions were compared between the two groups. Inter-group comparisons were performed using the chi-square test/Fisher’s exact test， the t-test， and the Mann-Whitney U test for categorical data， continuous data in normal distribution， and continuous data in non-normal distribution， respectively. The Kaplan-Meier survival curves were generated and compared using the log-rank test.  Results  The ORR and DCR of the study group were 35.0% and 80.0%， respectively， which were not significantly different from those of the control group （bothP>0.05）. The 1-year survival rate of the study group differed significantly from that of the control group （45.0% vs 20.0%，P<0.05）. The median PFS was 7.73 （95% confidence interval ［CI］：4.39‍ ‍— ‍‍11.01） months in the study group and 4.17 （95%CI：3.48‍ ‍— ‍‍4.85） months in the control group， and the difference was statistically significant （P<0.01）. The median OS was 11.77 （95%CI：8.07‍ ‍— ‍‍15.47） months in the study group and 7.97 （95%CI：5.84‍ ‍— ‍‍10.09） months in the control group， which were not statistically significant （P>0.05）. Across all grades of adverse reactions， the study group showed significantly higher incidence rates of hand-foot syndrome （62.5% vs 34.3%，χ2=5.945，P<0.05） and elevated blood pressure （42.5% vs 20.0%，χ2=4.343，P<0.05） than the control group. There were no significant differences in the incidence rates of adverse reactions of grade Ⅲ or above between the two groups （all P>0.05）.  Conclusion  Apatinib mesylate combined with GC+camrelizumab is superior to GC+camrelizumab in prolonging the PFS but not in terms of the OS， with controllable toxic side effects， which is a safe and effective treatment regimen.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    ROA JC, GARCÍA P, KAPOOR VK, et al. Gallbladder cancer[J]. Nat Rev Dis Primers, 2022, 8( 1): 69. DOI: 10.1038/s41572-022-00398-y.
    [2]
    YIN XY, XU QC. Surgical treatment of gallbladder cancer: Current status and advances[J]. J Clin Hepatol, 2024, 40( 12): 2366- 2370. DOI: 10.12449/JCH241205.

    殷晓煜, 许琼聪. 胆囊癌手术治疗的现状与进展[J]. 临床肝胆病杂志, 2024, 40( 12): 2366- 2370. DOI: 10.12449/JCH241205.
    [3]
    VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362( 14): 1273- 1281. DOI: 10.1056/NEJMoa0908721.
    [4]
    DU LW, LIU JS. Research advances in targeted therapy for gallbladder carcinoma[J]. J Clin Hepatol, 2023, 39( 12): 2965- 2969. DOI: 10.3969/j.issn.1001-5256.2023.12.032.

    杜丽文, 刘建生. 胆囊癌的靶向治疗研究进展[J]. 临床肝胆病杂志, 2023, 39( 12): 2965- 2969. DOI: 10.3969/j.issn.1001-5256.2023.12.032.
    [5]
    YI M, ZHENG X, NIU M, et al. Combination strategies with PD-1/PD-L1 blockade: Current advances and future directions[J]. Mol Cancer, 2022, 21( 1): 28. DOI: 10.1186/s12943-021-01489-2.
    [6]
    OH DY, HE AR, QIN SK, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin(GemCis) in patients(pts) with advanced biliary tract cancer(BTC): TOPAZ-1[J]. J Clin Oncol, 2022, 40( 4_suppl): 378. DOI: 10.1200/jco.2022.40.4_suppl.378.
    [7]
    KELLEY RK, UENO M, YOO C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer(KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 401( 10391): 1853- 1865. DOI: 10.1016/S0140-6736(23)00727-4.
    [8]
    LIU YB, CHEN W. Attach importance to the clinical and basic research on gallbladder carcinoma[J]. Chin J Dig Surg, 2025, 24( 1): 64- 71. DOI: 10.3760/cma.j.cn115610-20241227-00588.

    刘颖斌, 陈炜. 重视胆囊癌的临床和基础研究[J]. 中华消化外科杂志, 2025, 24( 1): 64- 71. DOI: 10.3760/cma.j.cn115610-20241227-00588.
    [9]
    LIU ZL, CHEN HH, ZHENG LL, et al. Angiogenic signaling pathways and anti-angiogenic therapy for cancer[J]. Signal Transduct Target Ther, 2023, 8( 1): 198. DOI: 10.1038/s41392-023-01460-1.
    [10]
    LIANG JM, GU WG, JIN J, et al. Efficacy and safety of apatinib as third-or further-line therapy for patients with advanced NSCLC: A retrospective study[J]. Ther Adv Med Oncol, 2020, 12: 1758835920968472. DOI: 10.1177/1758835920968472.
    [11]
    YUAN S, FU Q, ZHAO L, et al. Efficacy and safety of apatinib in patients with recurrent or refractory melanoma[J]. Oncologist, 2022, 27( 6): e463- e470. DOI: 10.1093/oncolo/oyab068.
    [12]
    HU JK, LI XM, WANG YP, et al. SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: A case report[J]. Front Immunol, 2024, 15: 1410284. DOI: 10.3389/fimmu.2024.1410284.
    [13]
    YANG YJ, KE TY, LIU SX, et al. Synergistic sensitization of apatinib mesylate and radiotherapy on hepatocarcinoma cells in vitro[J]. J Jilin Univ Med Ed, 2024, 50( 4): 1009- 1015. DOI: 10.13481/j.1671-587X.202404015.

    杨永净, 柯天洋, 刘士新, 等. 甲磺酸阿帕替尼联合放疗对肝癌HepG2细胞的体外协同增敏作用[J]. 吉林大学学报(医学版), 2024, 50( 4): 1009- 1015. DOI: 10.13481/j.1671-587X.202404015.
    [14]
    WANG DX, YANG X, LONG JY, et al. The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: A prospective clinical study[J]. Front Oncol, 2021, 11: 646979. DOI: 10.3389/fonc.2021.646979.
    [15]
    RAO JH, WU C, ZHANG H, et al. Efficacy and biomarker analysis of neoadjuvant carrizumab plus apatinib in patients with local advanced biliary tract cancers[J]. J Clin Oncol, 2021, 39( 15_suppl): e16126. DOI: 10.1200/jco.2021.39.15_suppl.e16126.
    [16]
    EISENHAUER EA, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009, 45( 2): 228- 247. DOI: 10.1016/j.ejca.2008.10.026.
    [17]
    SUN XH, REN T, GENG YJ, et al. A largescale multicenter retrospective study of current surgical treatment modalities and pathological characteristics of patients with gallbladder cancer in China: A report of 4, 345 cases[J]. Chin J Pract Surg, 2021, 41( 1): 99- 106. DOI: 10.19538/j.cjps.issn1005-2208.2021.01.18.

    孙旭恒, 任泰, 耿亚军, 等. 中国胆囊癌外科治疗现状与病理学特征多中心回顾性研究(附4 345例报告)[J]. 中国实用外科杂志, 2021, 41( 1): 99- 106. DOI: 10.19538/j.cjps.issn1005-2208.2021.01.18.
    [18]
    RIZZO A, RICCI AD, BRANDI G. Recent advances of immunotherapy for biliary tract cancer[J]. Expert Rev Gastroenterol Hepatol, 2021, 15( 5): 527- 536. DOI: 10.1080/17474124.2021.1853527.
    [19]
    ZHAO HT, WANG SS. Critical issues in conversion therapy and sequential surgical management of gallbladder carcinoma[J]. Chin J Pract Surg, 2023, 43( 11): 1214- 1222. DOI: 10.19538/j.cjps.issn1005-2208.2023.11.03.

    赵海涛, 王闪闪. 胆囊癌转化治疗及序贯手术治疗的几个关键问题[J]. 中国实用外科杂志, 2023, 43( 11): 1214- 1222. DOI: 10.19538/j.cjps.issn1005-2208.2023.11.03.
    [20]
    LI H. 65P A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and Gemox regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers[J]. Ann Oncol, 2022, 33: S570. DOI: 10.1016/j.annonc.2022.07.093.
    [21]
    SHI GM, HUANG XY, WU D, et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-center, single-arm, phase 2 study[J]. Signal Transduct Target Ther, 2023, 8( 1): 106. DOI: 10.1038/s41392-023-01317-7.
    [22]
    ZHU CP, XUE JN, WANG YC, et al. Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer[J]. Front Immunol, 2023, 14: 1109292. DOI: 10.3389/fimmu.2023.1109292.
    [23]
    GUPTA P, CANONICO ME, FAABORG-ANDERSEN C, et al. Updates in the management of cancer therapy-related hypertension[J]. Curr Opin Cardiol, 2024, 39( 4): 235- 243. DOI: 10.1097/HCO.0000000000001127.
    [24]
    MCLELLAN B, CIARDIELLO F, LACOUTURE ME, et al. Regorafenib-associated hand-foot skin reaction: Practical advice on diagnosis, prevention, and management[J]. Ann Oncol, 2015, 26( 10): 2017- 2026. DOI: 10.1093/annonc/mdv244.
    [25]
    VERSMISSEN J, MIRABITO COLAFELLA KM, KOOLEN SLW, et al. Vascular cardio-oncology: Vascular endothelial growth factor inhibitors and hypertension[J]. Cardiovasc Res, 2019, 115( 5): 904- 914. DOI: 10.1093/cvr/cvz022.
    [26]
    XIA H, ZHOU C, LUO ZX, et al. Apatinib-induced hand-foot skin reaction in Chinese patients with liver cancer[J]. Front Oncol, 2021, 11: 624369. DOI: 10.3389/fonc.2021.624369.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (344) PDF downloads(40) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return